Filtered By:
Cancer: Epithelial Cancer
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 20002 results found since Jan 2013.
The involvement of MALAT1-ALKBH5 signaling axis into proliferation and metastasis of human papillomavirus-positive cervical cancer
Cancer Biol Ther. 2023 Dec 31;24(1):2249174. doi: 10.1080/15384047.2023.2249174.ABSTRACTInfection with high-risk human papillomavirus (HPV), for example, with types 16 and 18, is closely associated with cervical cancer development, which continues to threaten women's health globally. Although HPV oncogenes have been recognized as the main cause of transformation of normal cervical epithelial cells, non-coding RNA could also be involved in the initiation and promotion of cervical cancer development. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), a well-documented long non-coding RNA (lncRNA), has been prev...
Source: Cancer Biology and Therapy - August 28, 2023 Category: Cancer & Oncology Authors: Suzhen Wu Lili Liu Huanying Xu Qiaoling Zhu Minhua Tan Source Type: research
MicroRNA and gynecological cancers: Focus on miR-195
Pathol Res Pract. 2023 Aug 24;249:154784. doi: 10.1016/j.prp.2023.154784. Online ahead of print.ABSTRACTDifferent cancer types have been shown to have down-regulated expression levels of miR-195 as an anti-tumor agent. MiR-195 family members can inhibit cancer cell proliferation, angiogenesis, epithelial-mesenchymal transition and metastases, immunosuppression, glycolysis, drug resistance, and cancer stem cell development by targeting the 3'-UTR of the mRNA of different pro-tumor genes. MiR-195 identified as a tumor suppressor miR in a variety of cancers, most notably gynecological malignancies such as cervical, endometria...
Source: Pathology, Research and Practice - August 28, 2023 Category: Pathology Authors: Amirhossein Davoodvandi Mahdi Rafiyan Mohammad Ali Mansournia Nesa Rajabpoor Nikoo Maryam Saati Mansooreh Samimi Zatollah Asemi Source Type: research
Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment
CONCLUSIONS: In patients with newly diagnosed (advanced) or recurrent high-grade serous or endometrioid ovarian cancer, niraparib maintenance therapy improved progression-free survival compared with no maintenance therapy in tumours with HRD or HRP (GRADE: High). Because we identified no studies on the clinical utility of HRD testing, we cannot comment on how it would affect patient decisions and clinical outcomes.Over a 5-year time horizon, HRD testing for people with BRCA wild type could save $4,509 per person and lead to a loss of 0.116 QALY. The findings of our economic analyses are dependent on assumptions about the u...
Source: Ontario Health Technology Assessment Series - August 28, 2023 Category: General Medicine Authors: Ontario Health (Quality) Source Type: research
Exosome nanovesicles as potential biomarkers and immune checkpoint signaling modulators in lung cancer microenvironment: recent advances and emerging concepts
J Exp Clin Cancer Res. 2023 Aug 29;42(1):221. doi: 10.1186/s13046-023-02753-7.ABSTRACTLung cancer remains the leading cause of cancer-related deaths globally, and the survival rate remains low despite advances in diagnosis and treatment. The progression of lung cancer is a multifaceted and dynamic phenomenon that encompasses interplays among cancerous cells and their microenvironment, which incorporates immune cells. Exosomes, which are small membrane-bound vesicles, are released by numerous cell types in normal and stressful situations to allow communication between cells. Tumor-derived exosomes (TEXs) possess diverse neo...
Source: Clinical Lung Cancer - August 28, 2023 Category: Cancer & Oncology Authors: Naushad Ahmad Khan Mohammad Asim Kabir H Biswas Amani N Alansari Harman Saman Mohammad Zahid Sarwar Kudaibergen Osmonaliev Shahab Uddin Source Type: research
Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment
CONCLUSIONS: In patients with newly diagnosed (advanced) or recurrent high-grade serous or endometrioid ovarian cancer, niraparib maintenance therapy improved progression-free survival compared with no maintenance therapy in tumours with HRD or HRP (GRADE: High). Because we identified no studies on the clinical utility of HRD testing, we cannot comment on how it would affect patient decisions and clinical outcomes.Over a 5-year time horizon, HRD testing for people with BRCA wild type could save $4,509 per person and lead to a loss of 0.116 QALY. The findings of our economic analyses are dependent on assumptions about the u...
Source: Ontario Health Technology Assessment Series - August 28, 2023 Category: General Medicine Authors: Ontario Health (Quality) Source Type: research
Same day service: A genetic testing station model to improve germline genetic testing in patients with ovarian cancer
CONCLUSIONS: The GTS reduces barriers to care and facilitates discussion of precision treatment within a timely fashion while optimizing GC clinic time. Access improvement remains integral to improving uptake of genetic testing.PMID:37639903 | DOI:10.1016/j.ygyno.2023.07.019
Source: Gynecologic Oncology - August 28, 2023 Category: Cancer & Oncology Authors: Nicole Marjon Rosa Guerra Alexandra Freeman Julie Mak Stephanie Cheung Kelly Gordon Amie Blanco Stefanie Ueda Lee-May Chen Source Type: research
Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment
CONCLUSIONS: In patients with newly diagnosed (advanced) or recurrent high-grade serous or endometrioid ovarian cancer, niraparib maintenance therapy improved progression-free survival compared with no maintenance therapy in tumours with HRD or HRP (GRADE: High). Because we identified no studies on the clinical utility of HRD testing, we cannot comment on how it would affect patient decisions and clinical outcomes.Over a 5-year time horizon, HRD testing for people with BRCA wild type could save $4,509 per person and lead to a loss of 0.116 QALY. The findings of our economic analyses are dependent on assumptions about the u...
Source: Ontario Health Technology Assessment Series - August 28, 2023 Category: General Medicine Authors: Ontario Health (Quality) Source Type: research
The involvement of MALAT1-ALKBH5 signaling axis into proliferation and metastasis of human papillomavirus-positive cervical cancer
Cancer Biol Ther. 2023 Dec 31;24(1):2249174. doi: 10.1080/15384047.2023.2249174.ABSTRACTInfection with high-risk human papillomavirus (HPV), for example, with types 16 and 18, is closely associated with cervical cancer development, which continues to threaten women's health globally. Although HPV oncogenes have been recognized as the main cause of transformation of normal cervical epithelial cells, non-coding RNA could also be involved in the initiation and promotion of cervical cancer development. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), a well-documented long non-coding RNA (lncRNA), has been prev...
Source: Cancer Biology and Therapy - August 28, 2023 Category: Cancer & Oncology Authors: Suzhen Wu Lili Liu Huanying Xu Qiaoling Zhu Minhua Tan Source Type: research
Epithelial-to-mesenchymal transition status correlated with ultrastructural features, and TP53 mutation in patient-derived oral cancer cell lines
CONCLUSIONS: Cellular migratory properties are associated with cellular ultrastructure, epithelial-to-mesenchymal transition status and the status of TP53 mutation in the genome.PMID:37639153 | DOI:10.1007/s11033-023-08720-x
Source: Mol Biol Cell - August 28, 2023 Category: Molecular Biology Authors: Sushant S Navarange Sanjay M Bane Darshan Mehta Sanket Shah Sanjay Gupta Sanjeev K Waghmare Source Type: research
Same day service: A genetic testing station model to improve germline genetic testing in patients with ovarian cancer
CONCLUSIONS: The GTS reduces barriers to care and facilitates discussion of precision treatment within a timely fashion while optimizing GC clinic time. Access improvement remains integral to improving uptake of genetic testing.PMID:37639903 | DOI:10.1016/j.ygyno.2023.07.019
Source: Gynecologic Oncology - August 28, 2023 Category: Cancer & Oncology Authors: Nicole Marjon Rosa Guerra Alexandra Freeman Julie Mak Stephanie Cheung Kelly Gordon Amie Blanco Stefanie Ueda Lee-May Chen Source Type: research
Exosome nanovesicles as potential biomarkers and immune checkpoint signaling modulators in lung cancer microenvironment: recent advances and emerging concepts
J Exp Clin Cancer Res. 2023 Aug 29;42(1):221. doi: 10.1186/s13046-023-02753-7.ABSTRACTLung cancer remains the leading cause of cancer-related deaths globally, and the survival rate remains low despite advances in diagnosis and treatment. The progression of lung cancer is a multifaceted and dynamic phenomenon that encompasses interplays among cancerous cells and their microenvironment, which incorporates immune cells. Exosomes, which are small membrane-bound vesicles, are released by numerous cell types in normal and stressful situations to allow communication between cells. Tumor-derived exosomes (TEXs) possess diverse neo...
Source: Cell Research - August 28, 2023 Category: Cytology Authors: Naushad Ahmad Khan Mohammad Asim Kabir H Biswas Amani N Alansari Harman Saman Mohammad Zahid Sarwar Kudaibergen Osmonaliev Shahab Uddin Source Type: research
Epithelial-to-mesenchymal transition status correlated with ultrastructural features, and TP53 mutation in patient-derived oral cancer cell lines
CONCLUSIONS: Cellular migratory properties are associated with cellular ultrastructure, epithelial-to-mesenchymal transition status and the status of TP53 mutation in the genome.PMID:37639153 | DOI:10.1007/s11033-023-08720-x
Source: Molecular Biology Reports - August 28, 2023 Category: Molecular Biology Authors: Sushant S Navarange Sanjay M Bane Darshan Mehta Sanket Shah Sanjay Gupta Sanjeev K Waghmare Source Type: research
MicroRNA and gynecological cancers: Focus on miR-195
Pathol Res Pract. 2023 Aug 24;249:154784. doi: 10.1016/j.prp.2023.154784. Online ahead of print.ABSTRACTDifferent cancer types have been shown to have down-regulated expression levels of miR-195 as an anti-tumor agent. MiR-195 family members can inhibit cancer cell proliferation, angiogenesis, epithelial-mesenchymal transition and metastases, immunosuppression, glycolysis, drug resistance, and cancer stem cell development by targeting the 3'-UTR of the mRNA of different pro-tumor genes. MiR-195 identified as a tumor suppressor miR in a variety of cancers, most notably gynecological malignancies such as cervical, endometria...
Source: Cell Research - August 28, 2023 Category: Cytology Authors: Amirhossein Davoodvandi Mahdi Rafiyan Mohammad Ali Mansournia Nesa Rajabpoor Nikoo Maryam Saati Mansooreh Samimi Zatollah Asemi Source Type: research
Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment
CONCLUSIONS: In patients with newly diagnosed (advanced) or recurrent high-grade serous or endometrioid ovarian cancer, niraparib maintenance therapy improved progression-free survival compared with no maintenance therapy in tumours with HRD or HRP (GRADE: High). Because we identified no studies on the clinical utility of HRD testing, we cannot comment on how it would affect patient decisions and clinical outcomes.Over a 5-year time horizon, HRD testing for people with BRCA wild type could save $4,509 per person and lead to a loss of 0.116 QALY. The findings of our economic analyses are dependent on assumptions about the u...
Source: Ontario Health Technology Assessment Series - August 28, 2023 Category: General Medicine Authors: Ontario Health (Quality) Source Type: research
